Neurocrine Biosciences (NASDAQ:NBIX): The mean estimate for the short term price target for Neurocrine Biosciences (NASDAQ:NBIX) stands at $68.89 according to 9 Analysts. The higher price target estimate for the stock has been calculated at $96 while the lower price target estimate is at $57.
Many analysts have stated their opinion on the company shares. BMO Capital initiates coverage on Neurocrine Biosciences (NASDAQ:NBIX) . Analysts at the BMO Capital have a current rating of Outperform on the shares. The rating by the firm was issued on April 7, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Chief Regulatory Officer) of Neurocrine Biosciences Inc, Lloyd-Smith Malcolm had sold 9,000 shares worth of $450,000 in a transaction dated May 31, 2016. In this transaction, 9,000 shares were sold at $50 per share.
Neurocrine Biosciences (NASDAQ:NBIX) stock ended Monday session in the red zone in a volatile trading. The stock closed down 1.71 points or 3.53% at $46.67 with 1,024,471 shares getting traded. Post opening the session at $47.88, the shares hit an intraday low of $46.295 and an intraday high of $48.71 and the price was in this range throughout the day. The company has a market cap of $4,044 million and the number of outstanding shares have been calculated to be 86,656,029 shares. The 52-week high of Neurocrine Biosciences (NASDAQ:NBIX) is $58.46 and the 52-week low is $31.25.
Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Companys two lead late-stage clinical programs are elagolix, a gonadotropin releasing hormone (GnRH) antagonist for womens health that is partnered with AbbVie Inc. (AbbVie), and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective, orally-active, non-peptide CRF receptor antagonist.